Alligator Bioscience will gain strong connections to both the world leading research performed by professor Mathias Uhlén at the SciLifeLab and the HPA project in Stockholm/Uppsala as well as the CREATE Health Translational Cancer Center at the University of Lund.
Alligator Bioscience will remain based in Medicon Village in Lund and with Sibylle Lenz as CEO.
In order to finance the continued development of Alligator Biosciences the company will carry out a combination of precedence emission and directed emissions of approximately 80 million SEK.
